Get the Stockscreener App
1.49
4.20%
0.06
After Hours:
1.52
0.03
+2.01%
Kala Bio Inc stock is traded at $1.49, with a volume of 237.21K.
It is up +4.20% in the last 24 hours and down -92.00% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$1.43
Open:
$1.43
24h Volume:
237.21K
Relative Volume:
0.25
Market Cap:
$10.46M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.1195
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
-1.97%
1M Performance:
-92.00%
6M Performance:
-55.79%
1Y Performance:
-71.72%
1-Day Range:
$1.42
$1.49
1-Week Range:
$1.40
$1.70
52-Week Range:
$1.10
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
1.49 | 10.04M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Using fundamentals and technicals on KALA BIO Inc.Treasury Yields & Safe Swing Trade Setup Alerts - newser.com
Intraday pattern recognizer results for KALA BIO Inc.CEO Change & AI Forecasted Entry/Exit Points - newser.com
Volume spikes in KALA BIO Inc. stock – what they meanJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How sentiment analysis helps forecast KALA BIO Inc.Trend Reversal & Daily Momentum Trading Reports - newser.com
How hedge fund analytics apply to KALA BIO Inc. stockJuly 2025 Final Week & Capital Protection Trading Alerts - newser.com
What to expect from KALA BIO Inc. in the next 30 days2025 Price Targets & Free Technical Confirmation Trade Alerts - newser.com
KALA BIO Inc. stock prediction for this weekPortfolio Growth Summary & Low Risk Growth Stock Ideas - newser.com
Custom watchlist performance reports with KALA BIO Inc.CEO Change & Verified Short-Term Plans - newser.com
BAKER BROS. ADVISORS LP Increases Stake in Kala Bio Inc. - GuruFocus
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
Is KALA BIO Inc a good long term investmentStock Rotation Strategies & Turn Market Volatility into Wealth - earlytimes.in
Is KALA BIO Inc. meeting your algorithmic filter criteria2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Quantitative breakdown of KALA BIO Inc. recent moveWeekly Investment Recap & Weekly Top Stock Performers List - newser.com
Forecasting KALA BIO Inc. price range with options dataJuly 2025 Retail & Technical Pattern Alert System - newser.com
Candlestick signals on KALA BIO Inc. stock todayWeekly Stock Recap & Real-Time Volume Analysis - newser.com
Mizuho Securities Downgrades KALA BIO(KALA.US) to Hold Rating, Cuts Target Price to $1.5 - 富途牛牛
Is KALA BIO Inc. stock supported by strong cash flowsJuly 2025 Catalysts & Weekly Breakout Stock Alerts - newser.com
Leadership watch: KALA BIO names new CEO, Aurion Biotech promotes execs - Eyes On Eyecare
Can KALA BIO Inc. stock surprise with earnings upsideNew Guidance & Safe Entry Momentum Tips - newser.com
Q3 Earnings Estimate for KALA BIO Issued By Lifesci Capital - Defense World
Published on: 2025-10-01 09:01:05 - newser.com
Kala Bio receives notice of event of default from Oxford Finance LLCSEC filing - MarketScreener
Kala Bio receives default notice, $29.1 million loan declared immediately due - Investing.com India
Kala Bio receives default notice, $29.1 million loan declared immediately due By Investing.com - Investing.com South Africa
KALA BIO, Inc. Receives Default Notice from Oxford Finance with Respect to Certain Loan and Security Agreement - MarketScreener
KALA BIO (NASDAQ:KALA) Rating Lowered to “Hold” at Lifesci Capital - Defense World
KALA BIO, Inc. Securities Lawsuit Investigation - Claim Depot
Kala Bio Shares Fall After Downgrade From Mizuho - MarketScreener
A Heavy Trading Day Sends Biotech And Finance Stocks Reeling - Finimize
Kala Bio Faces Diminishing Options After Eye Drug Failure - insights.citeline.com
Mizuho Downgrades KALA BIO to Neutral From Outperform, Price Target is $1.50 - MarketScreener
Kala Bio tanks on Phase IIb KPI-012 miss - The Pharma Letter
KALA BIO (NASDAQ:KALA) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure - Medical Dialogues
Electronic Arts, Kala Bio, Semtech - TradingView
KALA BIO (NASDAQ:KALA) Downgraded to “Neutral” Rating by LADENBURG THALM/SH SH - Defense World
KALA BIO (KALA) Price Target Increased by 23.00% to 31.36 - Nasdaq
KALA BIO (NASDAQ:KALA) Receives “Neutral” Rating from HC Wainwright - Defense World
Kala Bio’s corneal treatment fails to meet primary endpoint in trial - Investing.com Nigeria
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Former 10% owner |
Sep 30 '25 |
Sale |
1.60 |
216,801 |
345,993 |
97,120 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Jun 24 '25 |
Sale |
4.01 |
4,511 |
18,089 |
62,566 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 24 '25 |
Sale |
4.01 |
3,631 |
14,560 |
62,100 |
| Bazemore Todd | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
4,058 |
16,273 |
83,699 |
| Brazzell Romulus K | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
5,251 |
21,057 |
82,698 |
| Iwicki Mark T | Director |
Jun 24 '25 |
Sale |
4.01 |
13,227 |
53,040 |
258,433 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):